Pfizer’s Post-COVID Slump, But Pipeline Looks Strong 💊Pfizer’s Q3 earnings missed expectations due to lower COVID sales. But let’s be real, their pipeline is still solid—oncology, gene therapy, and rare diseases could keep the revenue flowing long-term. I’m holding for now, but it’s definitely a bumpy ride. Also, don’t forget about BOLT—I’m hearing it could take off soon, so keep an eye on that one.